Antonino Mannone, MD
Gastroenterology · Williamsville, NYNPI 1821073388
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 231 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 41.6% of the total.
Across 231 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$692
- Phathom Pharmaceuticals, Inc.$238
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$153
- Ironwood Pharmaceuticals, Inc$148
- Aimmune Therapeutics, Inc.$138
- plus $1K from 23 others
What the payments were for
- Food & beverage$4,41399%
- Education$311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 95 | $1,850 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $692 |
| Phathom Pharmaceuticals, Inc. | 11 | $238 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $153 |
| Ironwood Pharmaceuticals, Inc | 8 | $148 |
| Aimmune Therapeutics, Inc. | 6 | $138 |
| Johnson & Johnson(2 entities) | 6 | $128 |
| Sanofi | 5 | $120 |
| Ardelyx, Inc. | 4 | $101 |
| Nestle Healthcare Nutrition Inc. | 6 | $95 |
| Regeneron Healthcare Solutions, Inc. | 3 | $94 |
| Bristol Myers Squibb | 5 | $87 |
| Ferring Pharmaceuticals Inc. | 4 | $79 |
| Lilly USA, LLC | 3 | $60 |
| Braintree Laboratories, Inc. | 4 | $60 |
| Gilead | 2 | $59 |
| Boehringer Ingelheim | 3 | $53 |
| Amgen | 2 | $38 |
| Fresenius Kabi USA, LLC | 2 | $37 |
| Celltrion USA Inc. | 2 | $31 |
| Pfizer | 1 | $24 |
| Fujifilm Healthcare Americas Corporation | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Sandoz | 1 | $21 |
| Exact Sciences | 1 | $20 |
| AstraZeneca | 1 | $18 |
| Concordia Pharmaceuticals Inc. | 1 | $18 |
| Intercept Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$4,444 in reported general payments places this provider in the 65th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 111 | $102,568 |
| ZenpepLipase/Protease/Amylase | 31 | $58,681 |
| Mesalamine | 87 | $51,371 |
| CreonLipase/Protease/Amylase | 36 | $39,551 |
| Budesonide ErBudesonide | 20 | $20,544 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 107 | $18,197 |
| Ursodiol | 61 | $16,070 |
| Sucralfate | 55 | $8,846 |
| Mesalamine DrMesalamine | 11 | $7,632 |
| Pantoprazole Sodium | 440 | $6,718 |
| Balsalazide Disodium | 12 | $6,453 |
| Famotidine | 299 | $5,108 |
| MovantikNaloxegol Oxalate | 11 | $4,497 |
| Dexlansoprazole DrDexlansoprazole | 11 | $4,351 |
| Hydrocortisone | 15 | $3,162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $1,850 | $142,119147 claims |
| Aimmune Therapeutics, Inc.Zenpep | $138 | $58,68131 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $79 | $18,197107 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,682 gastroenterology providers in New York.
Other gastroenterology in Williamsville
- Maya SrivastavaWilliamsville$1.8M
- Ahmad KadhimWilliamsville$155K
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Melissa PalmerPlainview$1M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.